Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy (Q34547874)

2 August 2017

title

Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy (English)

1 reference

2 August 2017

1 reference

1 reference

1 reference

Gregory S Merrick

1

1 reference

2 August 2017

Wayne M Butler

2

1 reference

2 August 2017

Kent E Wallner

3

1 reference

2 August 2017

Robert W Galbreath

4

1 reference

2 August 2017

Zachariah A Allen

5

1 reference

2 August 2017

Brian Kurko

6

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

68

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

116-120

1 reference

Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

The role of androgen deprivation therapy combined with prostate brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

The role of hormonal therapy in prostate brachytherapy. Counterpoint.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Is Bicalutamide Equivalent to Goserelin for Prostate Volume Reduction before Radiation Therapy? A Prospective, Observational Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Complications of androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Neoadjuvant flutamide monotherapy for locally confined prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.061

10.1016/J.UROLOGY.2006.01.061

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference